The annual ceremony recognises the best performing companies in
Contacts
+44 1223 919760
IR@acaciapharma.com
+44 20 7638 9571
acaciapharma@citigatedewerogerson.com
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new products designed to improve the treatment and care of patients undergoing invasive medical procedures or cancer therapy. The Group’s pipeline includes near-market opportunities, which it plans to sell directly in the US through its own commercial operations, and in other territories through licensing and distribution agreements with selected partners.
The Group's pipeline includes:
- BARHEMSYS® (intravenous amisulpride) for post-operative nausea & vomiting (PONV) (NDA filed)
- ByFavo™ (intravenous remimazolam), an ultra-short-acting and reversible intravenous sedative/anaesthetic designed for use during invasive medical procedures, such as during colonoscopy and bronchoscopy (NDA filed), and
- APD403 (intravenous and oral amisulpride) for chemotherapy induced nausea & vomiting (CINV) (Phase 2)
Acacia Pharma is based in
Forward looking statement
This announcement includes forward-looking statements, which are based on current expectations and projections about future events. These statements may include, without limitation, any statements preceded by, followed by or including words such as “believe”, “expect”, “intend”, “may”, “plan”, “will”, “should”, “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements may and often do differ materially from actual results. These forward-looking statements are subject to risks, uncertainties and assumptions about the Company and its subsidiaries and investments, including, among other things, the development of its business, trends in its operating industry, and future capital expenditures and acquisitions. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Any forward-looking statements reflect the Company's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Group's business, results of operations, financial position, prospectus, growth or strategies and the industry in which it operates. Save as required by law or applicable regulation, the Company and its affiliates expressly disclaim any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise. Forward-looking statements speak only as of the date they are made.
© OMX, source